当前位置:首页 > 报告详情

葆元-Corporate-Presentation-January-2025-_vJPM_vF.pdf

上传人: c** 编号:604015 2025-02-03 27页 1.34MB

1、DRIVEN BY SCIENCE,FOCUSED ON LIFEDavid Hung,M.D.Founder,President,&CEOJ.P.Morgan Healthcare ConferenceJanuary 2025Forward looking statementsCertain statements included in this presentation(this“Presentation”)that are not historical facts are forward-looking statements for purposes of the safe harbor

2、 provisions under the United States Private Securities Litigation Reform Act of 1995.Forward-looking statements are sometimes accompanied by words such as“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”“should,”“would,”“plan,”“predict,”“potential,”“seem,”“seek,”“future,”“

3、outlook”and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.These forward-looking statements include,but are not limited to,our expectations the timing of FDA approval and commercial launch,expectations and timing of establishing

4、a commercial organization,a full NDA approval for taletrectinib for the treatment of advanced ROS1+NSCLC(line agnostic),the potential for taletrectinib to become a new therapeutic option for ROS1+NSCLC,taletrectinibs and safusidenibs best-in-class therapeutic potential,potential therapeutic benefit

5、of Nuvation Bios product candidates and planning and advancement of clinical studies for such product candidates,sufficiency of Nuvation Bios current cash balance to support operations in the near term,clinical study design,or the potential of the DDC platform.These statements are based on various a

6、ssumptions,whether or not identified in this Presentation,and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance.These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ f

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了Nuvation Bio公司及其在肿瘤治疗领域的研发进展。Nuvation Bio由David Hung博士创立,致力于开发新一代肿瘤治疗药物。公司的主要研发项目包括: 1. Taletrectinib(ROS1抑制剂):用于治疗ROS1阳性的非小细胞肺癌(NSCLC),已在中国获得批准,并在美国获得优先审评资格,预计2025年6月获得批准。 2. Safusidenib(mIDH1抑制剂):用于治疗弥漫性IDH1突变型胶质瘤,正在开展关键性临床试验。 3. NUV-1511(药物偶联剂):用于治疗多种实体瘤,正在进行I/II期临床试验。 4. NUV-868(BET选择性抑制剂):用于治疗多种实体瘤,已完成I期和Ib期临床试验。 Nuvation Bio拥有5.49亿美元的现金储备,预计2025年中期在美国成为商业阶段公司。公司拥有强大的研发团队和丰富的产品管线,致力于解决肿瘤治疗领域的未满足需求。
为什么Taletrectinib在ROS1+ NSCLC治疗中具有潜在优势? Safusidenib如何通过抑制mIDH1来治疗IDH1突变型胶质瘤? Nuvation Bio如何利用其强大的现金储备来支持其药物研发?
客服
商务合作
小程序
服务号
折叠